Trials (National Cancer Institute): Revision history

15 December 2025

• curprev 13:2413:24, 15 December 2025‎ Francine talk contribs‎ 9,562 bytes +162‎ No edit summary undo

6 December 2025

• curprev 12:4212:42, 6 December 2025‎ Lucas talk contribs‎ m 9,400 bytes +1,701‎ Update categories. undo

4 December 2025

• curprev 14:5114:51, 4 December 2025‎ Larysse talk contribs‎ 7,699 bytes +51‎ No edit summary undo

2 December 2025

• curprev 14:0014:00, 2 December 2025‎ Lucas talk contribs‎ m 7,648 bytes +90‎ Update categories. undo

4 December 2023

• curprev 19:1519:15, 4 December 2023‎ Francine talk contribs‎ 7,558 bytes +7,558‎ Created page with "{{forpatients}} {{forresearchers}} {{forproviders}} Go back to National Cancer Institute page '''NCTID''': NCT03425643 '''Title''': Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671) '''Study Summary''': This trial will evaluate the safety and efficacy of pembrolizumab (M..."